Patients with an hsCRP increase at day 30 , defined as > 10 % increase over baseline value , had higher 180-day mortality risk compared with those with unchanged or decreased 30-day hsCRP ( HR 2.29 , 95 % CI 1.16-4 .52 ; P = .017 ) .